Search

Author/Creator Subbiah, V.

11. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. (October 2022)

Authors:
Yap, T.A.; Ngoi, N.; Dumbrava, E.E.; Karp, D.D.; Rodon Ahnert, J.; Fu, S.; Hong, D.S.; Naing, A.; Pant, S.; Piha-Paul, S.A.; Subbiah, V.; Tsimberidou, A.M.; Dufner, D.; Rhudy, J.; Gore, S.; Ivy, S.P.; Yuan, Y.; Westin, S.N.; Mills, G.B.; Meric-Bernstam, F.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S7
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in patients (pts) with advanced solid tumors. (December 2016)

Authors:
Subbiah, V.; Combest, A.; Grilley-Olson, J.; Sharma, N.; Andrews, E.; Bobe, I.; Balkissoon, J.; Camp, A.; Masada, A.; Reitsma, D.; Bazhenova, L.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S118
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

13. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. Issue 1 (December 2015)

Authors:
Liu, X.; George, G.; Tsimberidou, A.; Naing, A.; Wheler, J.; Kopetz, S.; Fu, S.; Piha-Paul, S.; Eng, C.; Falchook, G.; Janku, F.; Garrett, C.; Karp, D.; Kurzrock, R.; Zinner, R.; Raghav, K.; Subbiah, V.; Hess, K.; Meric-Bernstam, F.; Hong, D.
Journal:
BMC cancer
Issue:
Volume 15:Issue 1(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗